Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

34
PERTUSSIS Pathogenesis,Clinical picture,Lab ,treatment & Prophylaxis By Syed Nafeez

description

Pathogenesis: B.Pertussis is an obligate human parasite, surviving only for brief periods outside the host. Source: Early cases,particularly in catarrhal stage Carriers Fomites Mode of transmission: Inhalation of infected aerosols (droplet infection) Habit:localized in cilia of resp.epitelium,doesn’t invade the bloodstream

Transcript of Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Page 1: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

PERTUSSISPathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

BySyed Nafeez

Page 2: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Pathogenesis:B.Pertussis is an obligate human parasite, surviving only for brief periods outside the host.Source: •Early cases,particularly in catarrhal stage•Carriers•FomitesMode of transmission:Inhalation of infected aerosols (droplet infection)Habit:localized in cilia of resp.epitelium,doesn’t invade the bloodstream

Page 3: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Infected cilia by B.pertussis bacilli

bacillus

cilia

Page 4: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Mechanism:Droplet nuclei containing B.pertussis are inhaled

Adherence & rapid multiplication on cilia of resp.epithelium of nasopharynx,trachea & bronchi

Liberation of toxins(PT,TCT)& other substances…(FHA,AC)

Paralyse cilia causing insitu Θ of natural defences of resp.tract

secondary infections Irritate cells excessive secretions cough & catarrhal sympt

Necrosis with polymorphonuclear obstruction of bronchioles ATELECTASIS infiltration diminished oxygenationInterstitial pneumonia,bronchopneumonia contributes to↑frequency of convulsions in infants

Page 5: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

TitleContent

Page 6: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Host response:

Humoral response by the production of IgA & pertussis toxin antibodies is effective.

These prevent attachment of the bacillus.

Page 7: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Clinical picture:

Pertussis has an insidious onset after an IP of 1-2 weeks & a protracted course comprising of 3 stages:• Catarrhal stage• Paroxysmal stage• Convalescent stage

Each lasting for an approximate of 2 weeks

Page 8: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Catarrhal stage:There’s -low grade fever,malaise

-catarrhal symptoms-sneezing, rhinorrhoea & lacrimation -dry,irritating cough

During this stage the person is highly infectious as large number of bacilli are sprayed in the droplets The disease can be arrested at this stage by antibiotic

treatment but ∆ is very difficult ‘coz of its resemblance to typical VIRAL URI wit flu like symptoms.

Page 9: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Paroxysmal stage:• Characterised by distinctive bouts of ↑frequency

& intensity of cough that’s explosive in nature• During each bout,the patient experiences violent

spasms of continuous coughing that almost empties the lungs following which there’s deep inspiration that produces the characteristic ‘WHOOP’

• The patient’s exhausted at the end of each bout.Post tussive vomiting,cyanosis & convulsions may occur.Young infants become apnoeic.

Page 10: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Pertussis Cough Video.3gp

Page 11: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

• About 40-80 bouts occur throughout the day,more severe at night,yielding thick mucous plugs.

• ‘WHOOP’ & major complications occur predominantly in children

• The paroxysmal coughing predominates in older children & adults.

Page 12: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

T• Blood changes are distinctive & aid in ∆.There’s

marked Leucocytosis with an absolute lymphocytosis. TLC-16,000-30,000/μL with 60-80% being

lymphocytes

lymphocytes in this blood smear from an 18-month-old  child with the infection have lobulated nuclei.The cytology of the cells could be mistaken  for neoplastic lymphocytes.

Lymphocytes with lobulated nuclei

Page 13: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Convalescent stage:There’s ↓frequency & severity of cough.

The disease lasts for 6-8 weeks,though it maybe very protracted as in premature infants,the malnourished, immunocompromised,people with genetic susceptibility.

Page 14: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Complications:• Pulmonary-pneumonia -sc emphysema -atelectasis• Neurological-epilepsy,paralysis• Miscellaneous-haemorrhage (sub-conjunctival,epistaxis)

-otitis media -dehydration,malnutrition• In adults-rib fractures,back pain,hearing

loss,urinary incontinence,hernias,rectal prolapse.

Directly by B.pertussis

Secondary infections

aspirational

Page 15: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Lab ∆:

Specimens: nasopharyngeal secretions blood(serum) for serological testingThese are processed through:i. Cultureii. Direct Fluorescent Ab testing iii. Serological techniques-Ab titres,ELISAiv. PCR

Page 16: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

i. Culture:Nasopharyngeal secretions required for culture are collected by

following 4 methods:1)Cough plate method: A culture plate of Bordet Gengou Glycerine Potato Blood Agar

is held 10-15 cm infront of patient’s mouth during a bout of spontaneous or induced cough,such that the resp. exudate impinges directly on the medium.

The plate’s sealed & incubated for 48-72 hrs. Advantage is that the specimen is innoculated directly,at bedside.

Page 17: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

2)Pernasal swab: A swab (dacron or calcium alginate) mounted on a flexible

nichrome wire, is passed along the floor of nasal cavity & material collected from the pharyngeal wall.

Yields the highest % of isolation.

Page 18: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

3)Nasopharyngeal aspiration: Collected through a soft catheter attached to a

syringe Is the ‘preferred’ specimen.

4)Postnasal/peroral swab: A cotton swab(West’s post nasal swab) is passed

through mouth & secretions from posterior pharyngeal wall,collected.

There’s possibility of salivary contamination.

Page 19: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

• Specimens should be innoculated immediately on BGGPB Agar or its modifications like Lacey’s DFP medium

• In case of delay,transport media are used: 0.25-0.5 ml of Casamino acid solution,pH-7.2 Modified Stuart’s medium Mischulow’s charcoal agar Modified Regan-Lowe medium:

Is a ½ strength charcoal agar supplemented with 10% horse blood & cephalexin(40mg/L)It Θ growth of nasopharyngeal flora.Is also the medium of choice for culture.

• Culture plates are incubated for 7 days at high humidity & temperature of 35-36̊ C .

• Should be checked for any growth after 48-72 hrs of innoculation & periodically thereafter.

Page 20: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

A positive culture shows the characteristic ‘bisected pearls’ or ‘mercury drop’ colonies.

Confluent growth shows aluminium paint

appearance

Microscopy shows a non motile,gram negative bacillus.

Page 21: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

ii. Direct FA testing:Used to identify the bacillus either in direct smears of clinical

specimens or from culture. Is inexpensive. Provides rapid diagnosis & yields positive results when cultures are

negative due to use of antibiotics. Lacks specificity & sensitivity due to cross-reactions with

nasopharyngeal flora…..hence,unreliable & no longer recommended.

Page 22: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

iii. Serological techniques:

Focus on identifying significant variations in IgG & IgA titres(upto 4 fold ↑) against relavant B.pertussis virulence factors in both acute & convalescent phases of the disease.

Hence,for accurate ∆,serum samples in both phases of disease are to be collected.

Rise in Ab titres is demonstrated by:• Agglutination not helpful as the rise in agglutinating &• Gel precipitation precipitating Abs doesn’t occur untill 3rd week • Complement fixation tests of illness• ELISA- highly specific

Proposed as diagnostic method in culture sensitive casesA significant ↑ in titres(8E -2fold) between acute & convalescent phase is diagnostic of the disease

Page 23: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

iv. PCR:Most sensitive method to ∆ Pertussis Specimen used – nasopharyngeal aspiration Primers for both B.pertussis & B.parapertussis

should be included Gives positive results even when the organism

can’t be cultured.

THE BOTTOM LINE:A major problem is the lack of access to diagnostic laboratory methods. Many

routine laboratories are not equipped for the diagnosis of B. pertussis infection. This is the result of a general medical misconception that B. pertussis infection does not frequently occur in the population

Page 24: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Treatment:B.Pertussis isn’t susceptible to penicillins

• Erythromycin is DOC adults-250-500mg/6th hr 14 days children-30-60mg/kg/day

• Clarithromycin• Azithromycin• Cotrimoxazole • Chloremphenicol Cough sedatives are not usefulCorticosteroids reserved in severe cases, reduce duration of paroxysmal stage.Adrenergic ᵦ2 stimulants,reduce severity of paroxysms, more useful in infants.

Page 25: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Prophylaxis:Preventing the spread of disease by isolation isn’t preferred

as max.infectivity is in early stage when ∆ is difficult.Hence,prophylactic measures mainly include:• immunoprophylaxis

Vaccines currently used: DPT/DTwP/Triple antigen vaccine DTaP Tdap

• Chemoprophylaxis• General prophylaxis

Page 26: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Immunoprophylaxis:1)DPT/DTwP/Triple antigen vaccine:

• Composed of diphteria & tetanus toxoids,killed B.pertussis(smooth phase-1 strain)adsorbed on aluminium phosphate.thiomersol as preservative

• Dosing schedule: 3 Primary doses-at 6,10 & 14 weeks of life 2 Booster doses-1st booster at 15-18 months -2nd at 5 years

• Dose & route:0.5 ml,IM• Site: AL aspect of thigh in infants or deltoid

Page 27: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

• Side-effects:Minor reactions: Localized to site-soreness,swelling,redness Systemic-fever,fussiness,drowsiness,anorexiaModerate reactions:Seen in about 1:100/1000 shots: Crying non-stop for 3 hrs or more Fever of 105̊ F or moreLess often in about 1:1750 shots: Seizures(convulsions,spasms,staring spells) Collapse or fainting-child becomes blue,pale,limp & non-

responsiveSevere reactions:rareProlonged seizures,↓consciousness,coma,permanent brain

damage & death.!!!DPT vaccine is contraindicated if moderate to severe reactions

occur.Also contraindicated below 6 weeks of life & above 6 yrs

Last for 1-2 daysTreat with analgesics

Page 28: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

2)DTaP Vaccine: Is an acellular vaccine with pertussis component consisiting of inactivated

pertussis toxin, filamentous hemagglutinin, pertactin, or fimbriae along with diphteria & tetanus toxoids in concentrations similar to DTwP vaccine.

Indicated for children of 6 weeks-6 years of life. Dosing schedule is the same.

Page 29: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

3)Tdap vaccine: Is an acellular vaccine with concentrations of diphteria

toxoid & pertussis component reduced to 1/10 of DTaP vaccine.

for adolescents between the ages of 10 and 18 years preservative free (which means that, like most new

vaccines, it doesn't contain thimerosal) A similar Tdap vaccine, Adacel, is being reviewed by the

FDA & might be available for people between the ages of 11 and 64, which would be good news for adults who also want protection against pertussis.

Page 30: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Prevention and treatment prophylaxis of secondary casesThe CDC has defined a close contact as: someone having face-to-face exposure within 3 feet of a symptomatic

patient someone who has had direct contact with respiratory, oral, or nasal

secretions from a symptomatic patient someone who has shared the same confined space for more than 1 hour

with a symptomatic person.Chemoprophylaxis is given with recommended antibiotics and dosage

regimens,identical to those used for treatment of active infection. should be started in the asympto-matic person within 21 days of cough onset in the index

patient. highly recommended for all children younger than 12 months and women in the third

trimester of pregnancy who have been exposed to pertussis

Page 31: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

Epidemiology:

• Predominantly a pediatric disease.• Incidence & mortality highest in 1st year of life.• Common in females than males at all ages. Worldwide distribution with most deaths occuring in Africa,

Asia,central & latin America. Occurs endemically & epidemically In recent years,there’s been resurgence of the disease in

USA & eastern european countries Also,there’s an ↑ in number of cases being reported in

Asia.

Page 32: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

The Statistics: According to WHO estimates,around 2.95 lakh persons

died of whooping cough in 2002. In developing countries,the case fatality rates range from

4-15% in infants About 10% of cases & 50% of deaths occur in children

<1yr In India, there’s been marked decline in reported cases

from 1987-2005 year cases reported 1987 1.63 lakh 2002 26700 2005 43955

Page 33: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

THANK YOU

Page 34: Pathogenesis,Clinical picture,Lab ∆,treatment & Prophylaxis

XCUSE me if u have slept

through!!

&